The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIT-1: Randomized phase II trail of pemetrexed-cisplatin plus bevacizumab or concurrent thoracic radiation therapy followed by surgery in stage IIIA (N2) nonsquamous non-small cell lung cancer.
 
Kazuya Takamochi
No Relationships to Disclose
 
Kenji Suzuki
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Boehringer Ingelheim (Inst); Merck (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Shionogi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Pfizer (Inst)
 
Satoshi Ishikura
Honoraria - AstraZeneca Japan; Hitachi Chemical; Zeria Pharmaceutical
 
Shunsuke Oyamada
No Relationships to Disclose
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - ASAHI INTECC; CAC Croit Corporation; Chugai Pharma; Daiichi Sankyo; Japan Tobacco Inc; Kowa; Kyowa Hakko Kirin; Ono Pharmaceutical; TSUMURA & CO.
Speakers' Bureau - 3H Clinical Trial; ASAHI INTECC; Asahi Kasei; Chugai Pharma; Kaken Pharmaceutical
Research Funding - 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); CAC Croit Corporation (Inst); Daiichi Sankyo (Inst); Facet Biotech (Inst); Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Hakko Kirin (Inst); Luminary Medical (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Puravida Technologies (Inst); Welby (Inst)
 
Ichiro Yoshino
No Relationships to Disclose
 
Hiroyuki Ito
No Relationships to Disclose
 
Norihito Okumura
No Relationships to Disclose
 
Fumihiro Tanaka
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst)
 
Hisashi Saji
No Relationships to Disclose
 
Masanori Tsuchida
No Relationships to Disclose
 
Hirotoshi Horio
No Relationships to Disclose
 
Satoshi Shiono
No Relationships to Disclose
 
Motoki Matsuura
No Relationships to Disclose
 
Norihiko Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD; Nihon Medi-Physics; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kiowa Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Toshiki Tanaka
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)